rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Current clinical guidelines recommend mutation analysis for select codons in KRAS and NRAS exons 2, 3, and 4 and BRAF V600E to guide therapy selection and prognostic stratification in advanced colorectal cancer.
|
31589789 |
2020 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E-Mutated Colorectal Cancer.
|
31566309 |
2019 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Detection of the BRAF V600E Mutation in Colorectal Cancer by NIR Spectroscopy in Conjunction with Counter Propagation Artificial Neural Network.
|
31208050 |
2019 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
<i>BRAF</i> (v-raf murine sarcoma viral oncogene homolog B1) V600E mutant colorectal cancer is associated with short survival.
|
30719102 |
2019 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Circulating 25(OH)D was also inversely associated with <i>BRAF</i> V600E-positive colorectal cancer (per 25 nmol/L increment: HR, 0.71; 95% CI, 0.50-1.01).
|
30842127 |
2019 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Previous studies have reported that rafoxanide, as an inhibitor of BRAF V600E mutant protein, inhibits the growth of colorectal cancer, multiple myeloma, and skin cancer.
|
31678170 |
2019 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Non-V600E BRAF mutations and EGFR signaling pathway in colorectal cancer.
|
30963570 |
2019 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The US Food and Drug Administration approved a liquid biopsy test for EGFR-activating mutations in patients with non-small-cell lung cancer as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in non-small-cell lung cancer. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma.
|
30883505 |
2019 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Here, we investigate molecular responses upon single and multi-target treatments, over time, using BRAF(V600E) mutant colorectal cancer cells as a model system.
|
29970458 |
2018 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The US FDA approved a liquid biopsy test for EGFR activating mutations in patients with non-small cell lung cancer (NSCLC) as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in NSCLC. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma.
|
30335711 |
2018 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Clinical Significance of BRAF Non-V600E Mutations in Colorectal Cancer: A Retrospective Study of Two Institutions.
|
30463788 |
2018 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In the context of colorectal cancer, we present a method for constructing a surrogate biomarker that is able to predict with high accuracy whether a sample belongs to the "BRAF-positive" group, a high-risk group comprising V600E BRAF mutants and BRAF-mutant-like tumors.
|
28523274 |
2017 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression.
|
27354468 |
2017 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Alterations in <i>MEK1/2</i> occur in cancers, both in the treatment-naïve state and following targeted therapies, most notably BRAF and MEK inhibitors in <i>BRAF</i>-V600E-mutant melanoma and colorectal cancer.
|
28655712 |
2017 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF was mutated in 7.6% (484 of 6353) of colorectal cancer and 9.1% (29 of 317) of SBA samples, but V600E mutations were much less common in SBA, representing only 10.3% (3 of 29) of BRAF-mutated cases.
|
28617917 |
2017 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Prognostic value of BRAF V600E mutation and microsatellite instability in Japanese patients with sporadic colorectal cancer.
|
27672042 |
2017 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Common BRAF(V600E)-directed pathway mediates widespread epigenetic silencing in colorectal cancer and melanoma.
|
26787892 |
2016 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Identification and Characterization of Small-Molecule Inhibitors to Selectively Target the DFG-in over the DFG-out Conformation of the B-Raf Kinase V600E Mutant in Colorectal Cancer.
|
27624806 |
2016 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Concomitant with such properties, EBI-907 exhibits potent and selective cytotoxicity against a broader range of BRAF(V600E)-dependent cell lines including certain colorectal cancer cell lines with innate resistance to Vemurafenib.
|
26810733 |
2016 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E mutation in colorectal cancer is associated with right-sided tumours and iron deficiency anaemia.
|
25862899 |
2015 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These findings support BGB-283 as a potent antitumor drug candidate with clinical potential for treating colorectal cancer harboring BRAF(V600E) mutation.
|
26208524 |
2015 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
VE1 immunohistochemistry predicts BRAF V600E mutation status and clinical outcome in colorectal cancer.
|
26496026 |
2015 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This improved classification of serrated lesions including immunohistochemical evaluation of BRAF V600E mutation may be the key to identify lesions with higher potential to progression into sessile serrated adenoma/polyp, and further to BRAF V600E-mutated colorectal cancer.
|
23887306 |
2014 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
An MAFG-containing corepressor complex induces CIMP in BRAF(V600E)-positive colorectal cancer.
|
25367952 |
2014 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, miR-145 might be used as a therapeutic target in the treatment of colorectal cancer patients with BRAF V600E mutation.
|
24248543 |
2014 |